Medicinal mushrooms and cancer therapy - translating a traditional practice into Western medicine

被引:174
作者
Sullivan, R
Smith, JE
Rowan, NJ
机构
[1] Canc Res UK, London W2A 3PX, England
[2] Univ Strathclyde, Dept Biosci, Glasgow G1 1XQ, Lanark, Scotland
[3] Athlone Inst Technol, Dept Hlth Serv, Athlone, Ireland
关键词
D O I
10.1353/pbm.2006.0034
中图分类号
N09 [自然科学史]; B [哲学、宗教];
学科分类号
01 ; 0101 ; 010108 ; 060207 ; 060305 ; 0712 ;
摘要
Modern medical practice relies heavily on the use of highly purified pharmaceutical compounds whose purity can be easily assessed and whose pharmaceutical activity and toxicity show clear structure-function relationships. In contrast, many herbal medicines contain mixtures of natural compounds that have not undergone detailed chemical analyses and whose mechanism of action is not known. Traditional folk medicine and ethno-pharmacology coupled to bioprospecting have been an importint Source of many anticancer agents as well as other medicines. With the current decline in the number of new molecular entities from the pharmaceutical industry, novel anticancer agents are being sought from traditional medicine. As the example of medicinal mushrooms demonstrates, however, translating traditional Eastern practices into acceptable evidence-based Western therapies is difficult. Different manufacturing standards, criteria of purity, and under-powered clinical trials make assessment of efficacy and toxicity by Western standards of clinical evidence difficult. Purified bioactive compounds derived from medicinal mushrooms are a potentially important new source of anticancer agents; their assimilation into Western drug discovery programs and clinical trials also provides a framework for the study and use of other traditional medicines.
引用
收藏
页码:159 / 170
页数:12
相关论文
共 45 条
[1]  
[Anonymous], 2002, Medicinal mushrooms: their therapeutic properties and current medical usage with special emphasis on cancer treatments
[2]   Ligand binding to the (1→3)-β-D-glucan receptor stimulates NFκB activation, but not apoptosis in U937 cells [J].
Battle, J ;
Ha, TZ ;
Li, CF ;
Della Beffa, V ;
Rice, P ;
Kalbfleisch, J ;
Browder, W ;
Williams, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 249 (02) :499-504
[3]  
BENZKY D, 1993, CHINESE MAT MED
[4]   Chemical glycobiology [J].
Bertozzi, CR ;
Kiessling, LL .
SCIENCE, 2001, 291 (5512) :2357-2364
[5]   (1->3)-beta-D-glucans as biological response modifiers: A review of structure-functional activity relationships [J].
Bohn, JA ;
BeMiller, JN .
CARBOHYDRATE POLYMERS, 1995, 28 (01) :3-14
[6]   Mushrooms, tumors, and immunity [J].
Borchers, AT ;
Stern, JS ;
Hackman, RM ;
Keen, CL ;
Gershwin, ME .
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1999, 221 (04) :281-293
[7]  
Cassileth BR, 2000, SUPPORT CARE CANCER, V8, P16
[8]  
Chang ShuTing, 1999, International Journal of Medicinal Mushrooms, V1, P139
[9]  
CURT GA, 1998, ONCOLOGIST, V3, P64
[10]  
FUGIMOTO S, 1979, JPN J SURG, V3, P190